Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Batoclimab in CIDP
2024-518364-12-00Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Immunovant, Inc. Primary endpoint: Proportion of participants with TEAEs, SAEs, and TEAEs leading to study treatment discontinuation. Started Apr 2025; status: completed.
02
Drugs
batoclimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-518364-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518364-12-00.